Please login to the form below

Not currently logged in
Email:
Password:

Pfizer finalises deals for Ferrosan Consumer Health and Excaliard

US pharma company completes purchase of skincare specialist Excaliard Pharmaceuticals and dietary and lifestyle firm Ferrosan

Pfizer has completed two acquisitions that develop its interests in the skincare and consumer products markets.

The US pharma company has finalised its deals to buy Ferrosan Consumer Health from private equity firm Altor as well as Excaliard Pharmaceuticals, a US biopharma company focused on developing novel drugs for the treatment of skin fibrosis.

Pfizer's acquisition of Excaliard will see the pharma company gain full rights to the company's investigational treatments, including its phase II candidate EXC 001.

The drug is being developed to limit the process of skin fibrosis by inhibiting the expression of the body's connective tissue growth factor – a cause of skin scarring following surgery or injury. This is a therapy area for which there is currently no FDA approved medication.

According to Pfizer, phase II trials have been positive in reducing skin scarring, with the company keen to develop the treatment further.

Jose-Carlos Gutierrez-Ramos, senior vice president, Biotherapeutics, Worldwide Research and Development at Pfizer, said: “It is imperative at Pfizer that we continue to develop new and innovative treatments to address unmet medical needs.

“Acquiring Excaliard allows us to continue the development of its lead compound EXC 001 to potentially fill a gap and bring a novel new treatment to patients.”

The Ferrosan deal, originally announced in February, will see Pfizer enhance its presence in the Nordic region, as well as Russia and Ukraine, where Ferrosan is well-established.

Its products include the Centrum multivitamins brand and Caltrate, a calcium supplement.

Paul Sturman, president of Pfizer Consumer Healthcare, said Ferrosan was a “strong fit” for Pfizer's consumer business, which is looking to expand in more emerging markets.

Financial terms of both deals were undisclosed, however, Excaliard's shareholders, which include Isis Pharmaceuticals, will received both an upfront payment as well as certain milestone rewards if certain development and commercialisation objectives are met.

5th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics